Home > All insights > Drug Creation Platform Provider ABSCI Files for $100 Million US IPO
Daily Market Update
Drug Creation Platform Provider ABSCI Files for $100 Million US IPO

Esther Thin

AbSci Corporation, a drug creation platform provider, has filed Form S-1 Registration Statement on June 30, 2021 with the U.S. Securities and Exchange Commission to raise up to $100 million IPO. Pricing terms are yet to announce.

The company replaces fragmented steps and inefficiencies of the conventional biologic drug discovery and cell line development processes with our fully integrated, end-to-end platform designed to create new and better biologics and accelerate their advancement into clinical trials and ultimately into the marketplace.

The Vancouver, Washington-based company was founded in 2011 and booked $5 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq Global Market under the symbol “ABSI.” J.P. Morgan, Credit Suisse, BofA Securities, Cowen, and Stifel are underwriters of the IPO.

The company engages Goodwin Procter LLP as US Securities Counsel, and Ernst & Young LLP as Independent Auditor.

#ipo #nasdaq #AbSci #drug #plaform




Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,

namely NYSE, Nasdaq and OTC Markets.

Should you interested to list your company in US Stock Market,

please contact us at [email protected]